Related by context. All words. (Click for frequent words.) 72 CALGB 71 BCIRG 71 RTOG 69 multicentre randomized 67 Radiation Therapy Oncology 67 SABCS 66 SWOG 66 randomized Phase III 65 RE LY ® 65 NSABP 65 multicentre study 65 CLL8 65 ABCSG 65 multicenter prospective 65 NO# [002] 65 Phase Ib II 64 ExTRACT TIMI 64 EchoCRT 64 multicenter randomized clinical 64 TG MV 63 multicenter phase 63 ONTARGET 63 Phase Ib study 63 huN# DM1 63 multicentre 63 NCCTG 63 TMC# C# 63 AVADO 63 multicenter Phase II 63 subanalysis 63 RE LY 63 dose escalation clinical 63 CARE HF 63 Phase III randomized controlled 63 fosbretabulin 63 histone deacetylase HDAC inhibitor 63 Phase Ib clinical 63 ACRIN 62 Sorafenib HCC Assessment 62 Randomized Study 62 ECTRIMS 62 Kahalalide F 62 ToGA 62 pertuzumab 62 Group RTOG 62 ESMO 62 satraplatin Phase 62 J Clin Oncol 62 NCIC CTG 62 randomized multicenter trial 62 CAMMS# 62 STRIDE PD 62 multicenter randomized controlled 62 CALGB # [002] 62 NSABP B 62 BRIM3 62 National Surgical Adjuvant 62 Gynecologic Oncology Group 62 multicentric 61 Cooperative Oncology 61 noninferiority 61 riociguat 61 ELCAP 61 ISPOR 61 TRITON TIMI 61 Cancer EORTC 61 randomized multicenter 61 Phase #/#a 61 LUX Lung 61 Phase III VISTA 61 IASLC 61 multicenter study 61 ENDEAVOR IV 61 ASCO GI 61 prospective multicenter 61 UEGW 61 Multicenter 61 NICE SUGAR 61 HCV SPRINT 61 Taxotere ® 61 Multicenter Study 61 ELACYT 61 PROSTVAC TM 61 Group ECOG 61 ISEL 61 placebo controlled clinical 61 chemoradiotherapy 61 farletuzumab 61 neoadjuvant 61 Phase III randomized 61 preclinical efficacy 61 CHAMPION PCI 61 AASLD 61 PRESEPT 61 phase Ib 61 SUCCEED trial 60 multicenter 60 BRIM2 60 brivaracetam 60 CLL SLL 60 Solid Tumors 60 Phase 1b clinical trials 60 viral kinetic 60 NCCTG N# 60 AIR2 Trial 60 #F FDG PET 60 AACR NCI EORTC 60 neoadjuvant treatment 60 substudy 60 Genitourinary Cancers Symposium 60 multicenter trials 60 multicenter Phase 60 multicenter placebo controlled 60 gemcitabine carboplatin 60 MGd 60 EURIDIS 60 evaluating REVLIMID 60 Bowel Project 60 ongoing Phase 1b 60 Stenting Trial CREST 60 ENESTnd 60 oral FTY# 60 ROCKET AF 60 YONDELIS 60 RE LY trial 60 multiple myeloma MM 60 ICAAC IDSA 60 pan HDAC inhibitor 60 Phase IIIb clinical 60 CLARITY study 60 viral kinetics 60 Sipuleucel T 60 Doxil ® 60 RECIST Response Evaluation Criteria 60 mITT population 60 Faslodex 60 ERSPC 60 EFNS 60 HORIZONS AMI trial 60 prospective multicentre 60 Safinamide 60 ADVANCE PD 59 Enzastaurin 59 AACR San Antonio 59 pT2 59 Yondelis ® 59 mRCC 59 Abstract Number 59 solithromycin 59 Cloretazine ® 59 phase IIb study 59 pharmacokinetic PK 59 Response Evaluation Criteria 59 iSBTc 59 Virulizin ® 59 prostate cancer CaP 59 dose escalation trial 59 CIBMTR 59 standard chemotherapy regimen 59 randomized controlled Phase 59 EndoTAG TM -1 59 posaconazole 59 phase IIa clinical 59 sunitinib malate 59 pegylated interferon alfa 2b 59 Society CTOS 59 ON #.Na 59 League Against Rheumatism 59 CTRC AACR San Antonio 59 recurrent GBM 59 Carotid Revascularization Endarterectomy vs. 59 axitinib 59 gemcitabine Gemzar ® 59 Trandolapril 59 tanespimycin 59 assessing T DM1 59 trastuzumab emtansine T DM1 59 HDAC Inhibitor 59 Gastrointestinal Cancers Symposium 59 sorafenib Nexavar 59 multicenter clinical 59 phase IIIb 59 AACR #st Annual Meeting 59 enzastaurin 59 FOLPI 59 MORAb 59 ECCMID 59 Arch Surg 59 landmark ATHENA 59 ASTEROID 59 BR.# 59 BARI 2D 59 pain palliation 59 prospective nonrandomized 59 clinical pharmacology studies 59 pancreatic adenocarcinoma 59 Glucosamine Chondroitin Arthritis 59 ECASS 59 phase IIb clinical 59 EVEREST II 59 REACH Registry 59 HYVET 59 Malignant Lymphoma 59 EndoTAGTM 1 59 Targeted Therapy 59 Hematological 59 PRECiSE 59 Environ Health Perspect 59 Phase III psoriasis 59 IL# PE#QQR 59 multicenter randomized Phase III 59 Aplidin 59 Medical Oncology ESMO 59 TRO# 59 IIa trial 59 YONDELIS R 59 SUTENT ® 59 Aplidin R 59 multicenter randomized 59 Irinotecan 59 prospective randomized controlled 59 Antiviral Therapy 59 iniparib 59 placebo controlled Phase III 59 BEZ# 59 PROSTVAC ® 59 teriflunomide 59 ACUITY trial 59 randomized discontinuation trial 59 randomized controlled clinical 59 phase IIa 59 TAXUS IV 58 Preclinical Study 58 Pemetrexed 58 vinca alkaloid 58 nonmetastatic 58 SCCHN 58 FDG-PET/CT 58 LUMINATE 58 ASCO abstract 58 PROactive Study 58 Allovectin 7 ® 58 CALGB # [001] 58 papillary renal cell carcinoma 58 vitro cytotoxicity 58 Phase #b/#a 58 PFO migraine 58 pomalidomide 58 EUROGIN 58 Connective Tissue Oncology 58 prospective multicenter study 58 prospective observational 58 pharmacokinetic PK study 58 registrational 58 VITAL Trial 58 Phase IIb III 58 Cancer Res 58 PreCISe 58 mertansine 58 PSMA ADC 58 liposomal doxorubicin 58 HuMax EGFr 58 Telatinib 58 depsipeptide 58 Tesmilifene 58 Oncology ASTRO 58 Prostate Lung Colorectal 58 INTERCEPT platelets 58 ixabepilone 58 decitabine 58 ASCO GU 58 stage IIIB 58 ASH Annual Meeting 58 gefitinib Iressa 58 clinicopathological 58 Renal Cell Carcinoma RCC 58 Lenalidomide 58 Quinamed 58 HCV RESPOND 2 58 Cardiotoxicity 58 antitumor activity 58 multicenter randomized placebo controlled 58 pegylated liposomal doxorubicin 58 tocilizumab 58 neratinib 58 ICON7 58 Diabetologia 58 vidofludimus 58 prospective randomized placebo 58 paclitaxel poliglumex 58 ORMD 58 Late Breaker 58 EASL 58 pharmacodynamic effects 58 Denufosol 58 recurrent glioblastoma multiforme 58 Carfilzomib 58 BiTE antibody MT# 58 elacytarabine 58 MAGE A3 ASCI 58 prostate cancer AIPC 58 elotuzumab 58 Proxinium TM 58 sunitinib 58 Phase 2a trial 58 CBLC# 58 Ocrelizumab 58 #:#-# [031] 58 Phase Ib Clinical Trial 58 Phase 2b monotherapy 58 Marrow Transplantation 58 recurrent metastatic 58 tumor necrosis 58 ADAGIO study 58 Amrubicin 58 sunitinib Sutent 58 registrational Phase 58 CIMZIA TM certolizumab pegol 58 Edge STudy 58 Hexvix 58 adecatumumab 58 controlled multicenter Phase 58 CROI 58 ECCO ESMO 58 GW# [003] 58 prospectively defined 58 HSCT 58 ISTH 58 Phase 1a clinical 58 rALLy trial 58 ErbB2 positive 58 COPERNICUS 58 metastatic hormone refractory 58 Advanced Renal Cell 58 randomized multicentre 58 double blinded randomized 58 recurrent malignant glioma 58 refractory chronic lymphocytic 58 neoadjuvant therapy 58 tipranavir 58 relapsed refractory multiple myeloma 58 Biological Therapy 58 Chronic Lymphocytic Leukemia 58 prucalopride 58 EORTC NCI AACR 58 OLYMPIA registry 58 Dalbavancin 58 dose escalation Phase 58 Montalescot 58 bendamustine 58 REALITY Trial 58 Zybrestat 58 Autoimmunity 58 Hodgkin lymphoma HL 58 RECORD1 58 miRview mets 58 Val HeFT 58 relapsed MCL 58 registrational trial 58 NLX P# 58 Dacogen injection 58 antibody MT# 57 Arzerra ofatumumab 57 ENDEAVOR III 57 RADIANT 57 pancreatic carcinoma 57 EORTC NCI 57 BOLDER II 57 PLCO 57 Randomized Phase II 57 Phase #b/#a clinical 57 Epirubicin 57 ORAL Sync 57 Mantle Cell Lymphoma 57 BiTE R 57 Phase IIa trial 57 Phase 2b trial 57 Prostate AdenoCarcinoma Treatment 57 antibody blinatumomab MT#/MEDI-# 57 Prospective Randomized Trial 57 HER2 positive metastatic breast 57 RIO Lipids 57 lexidronam injection 57 TACI Ig 57 Velcade bortezomib 57 crizotinib PF # 57 NCT# ClinicalTrials.gov 57 antitumor effect 57 PEG IFN 57 Ranolazine 57 nab paclitaxel 57 Solorel TM 57 sipuleucel T 57 KRAS mutation 57 Degarelix 57 Clinical Antipsychotic Trials 57 Estrogen Receptor 57 Phase IIIb 57 Hsp# Inhibitor 57 Phase Ib clinical trials 57 fluoropyrimidine 57 evaluating tivozanib 57 Neoadjuvant 57 metastatic malignant 57 aurora kinase 57 Decitabine 57 pCR 57 immunohistochemical 57 CLORETAZINE TM VNP#M 57 prostate cancer mCRPC 57 Ozarelix 57 trabectedin 57 randomized Phase IIb 57 MabCampath 57 darinaparsin ZIO 57 Cardiology ESC 57 Phase 1b clinical 57 AVERROES 57 Kantarjian 57 coinfected patients 57 Novartis Zometa 57 Phase Ib 57 phase IIb 57 phase IIb trial 57 trastuzumab DM1 57 lymphadenectomy 57 rALLy clinical trial 57 refractory colorectal cancer 57 preclinically 57 randomized multicenter Phase III 57 nonrandomized 57 metastatic renal cell carcinoma 57 antibody MAb 57 Multiple Myeloma MM 57 mg BID dose 57 surgically resected 57 Temsirolimus 57 ponatinib 57 Phase IIIb study 57 BERKELEY CA UroToday.com 57 Multiple Ascending Dose 57 BrachySil TM 57 abstr 57 Fulvestrant 57 chemoradiation therapy 57 TNM staging 57 Gynecologic Cancer Society 57 receptor tyrosine kinase inhibitor 57 Acute Ischemic Stroke 57 Hematologic 57 Pharmacokinetic 57 MADIT CRT trial 57 RhuDex ® 57 PSN# [002] 57 SEER database 57 galiximab 57 Mycophenolate Mofetil 57 Ovarian PLCO Cancer 57 IFN α 57 Group B CALGB 57 TAXUS ATLAS 57 Aflibercept 57 trabedersen 57 histone deacetylase inhibitor 57 MADIT CRT 57 Eric Van Cutsem 57 KRAS status 57 AEG# 57 oral deforolimus 57 RoACTEMRA 57 Gastric Cancer 57 Neoplasia 57 Elocalcitol 57 RhuDex TM 57 irbesartan 57 afatinib 57 II Clinical Trial 57 Randomised 57 HGPIN 57 tesmilifene 57 CRp 57 Angiolix 57 TEMSO 57 CCX# 57 ADA Scientific Sessions 57 GELA 57 mCRC patients 57 PITX2 methylation 57 TIMP 1 57 VNP#M 57 OvaRex MAb 57 Traficet EN 57 Recurrent Chest Wall 57 ASCEND HF 57 Clinicaltrials.gov 57 FASEB J. 57 Halaven 57 Maximum Tolerated Dose MTD 57 CTAP# Capsules 57 CIMZIA ™ 57 paclitaxel carboplatin 57 Clinical Oncology Annual Meeting 57 trials RCTs 57 RhuDex R 57 PD LID 57 ABRF 57 VADT 57 miRview TM mets 57 number NCT# ClinicalTrials.gov 57 clinically localized prostate 57 dosing cohort 57 Prospective Randomized 57 Clinical Trial Results 57 mg/m2 dose 57 Abstract # 57 QUASAR validation study 57 prospective randomized multicenter 57 CIMZIA TM 56 ECOG 56 ASSERT 56 colon carcinoma 56 IMPACT IMmunotherapy 56 vascular disrupting agent 56 Ele Ferrannini 56 sustained virological response 56 PERSEUS 56 EASD 56 multikinase inhibitor 56 HPTN 56 Outpatient Setting 56 pivotal bioequivalence 56 Intervention Trial GAIT 56 PCI ExTRACT TIMI 56 Cloretazine 56 Azedra 56 Tarceva TM 56 intravesical therapy 56 GAMMAGARD 56 ANCHOR trial 56 LHRH receptor positive 56 TRANSFORMS 56 Hepatocellular Carcinoma 56 ASCO Annual Meeting 56 NPM1 56 Xelox 56 Myocet 56 ABSORB trial 56 NEVO RES 56 Transcatheter Cardiovascular Therapeutics TCT 56 genomic biomarker 56 plasma pharmacokinetics 56 gemcitabine Gemzar 56 PIX# [002] 56 EGFR HER2 56 olaparib 56 pharmacodynamic PD 56 apremilast 56 metastatic RCC 56 Pirfenidone 56 HepaSphere 56 mapatumumab 56 Tanespimycin 56 PRoFESS 56 EOquin TM 56 Digital Mammographic Imaging 56 Tumor Response 56 pharmacokinetics PK 56 trastuzumab Herceptin ® 56 Phase 2b study 56 AIR CF2 56 Randomized clinical trials 56 ZACTIMA 56 safety tolerability pharmacokinetic 56 genitourinary cancers 56 Myocardial Infarction 56 Pharmacodynamic 56 PLCO trial 56 Aggressive Reduction 56 EULAR 56 INCB# [001] 56 Cimzia ® certolizumab pegol 56 Advagraf 56 florbetaben 56 ESHO 56 Nexavar sorafenib 56 IRX 2 56 prospectively randomized 56 Omacetaxine 56 F FDG PET 56 PRESEPT Study 56 IMA# 56 chemotherapeutic regimen 56 aflibercept 56 EUS FNA 56 epoetin alpha 56 EACTS 56 Phase III TRIST 56 immunohistochemical staining 56 UPLYSO 56 MAGE A3 56 AZILECT ® 56 Placebo Controlled Trial 56 CA4P 56 relapsed MM 56 xCELLigence System 56 Factor VIIa 56 intraobserver 56 multicenter randomized double 56 ZD# [001] 56 nd Annual Meeting 56 MEND CABG 56 Screening Trial 56 Trofex 56 ANN INTERN MED 56 Antisense Pharma 56 randomized controlled clinical trials 56 Bowel Project NSABP 56 mTOR inhibitor 56 ISHLT 56 placebo controlled Phase 56 BIBW 56 inhibitor ARRY 56 Villejuif France 56 IGF 1R inhibitor 56 doxorubicin docetaxel 56 TAXUS Liberte Stent 56 biliary tract cancer 56 Deforolimus 56 Soft Tissue Sarcoma 56 cathepsin K inhibitor 56 NP2 Enkephalin 56 HQK 56 Lp PLA 2 56 Clinical Outcome 56 chemoprevention trials 56 Pertuzumab 56 Randomized trials 56 neurologic progression 56 Ceflatonin 56 thalidomide Thalomid 56 PCWP 56 Pharmacokinetics PK 56 ALTTO 56 Chronic Lymphocytic Leukemia CLL 56 BEACOPP 56 efficacy endpoint 56 CA9 SCAN 56 AUA Annual Meeting 56 EXPLORE Xa 56 Chicago Multidisciplinary Symposium 56 CRMD# 56 blinded randomized 56 immunostaining 56 Betaferon ® 56 Solorel 56 Subgroup analysis 56 Randomized Evaluation 56 lorvotuzumab mertansine 56 DAPT 56 visceral metastases 56 FOLFIRINOX 56 retrospectively analyzed 56 International Verapamil SR 56 Blinatumomab 56 unfractionated heparin UFH 56 ICAAC 56 clinical trial 56 refractory CLL 56 ARRY # 56 antiproliferative effects 56 Apaziquone 56 ACOMPLIA R 56 cancer mCRC 56 Hematological Malignancies 56 neoadjuvant chemotherapy 56 NCIC Clinical Trials 56 ganetespib 56 Afatinib 56 Hormone Refractory Prostate Cancer 56 Neck Cancer 56 seliciclib 56 Candesartan 56 Study Evaluating 56 subgroup analyzes 56 leukemia CLL 56 CAPRISA 56 randomized controlled trials RCTs 56 Acute Decompensated Heart Failure 56 ADHERE 56 INCB# [003] 56 Lymph node 56 Immunotherapeutic 56 Phase #/#a trial 56 SYMMETRY trial 56 Trastuzumab DM1 56 Dr. Fehlings 56 prostate carcinoma 56 liposomal amphotericin B 56 Xanafide 56 vismodegib 56 Ann Intern Med 56 Gilles Montalescot 56 NABTT 56 IV NSCLC 56 SIR Spheres 56 dose escalation study 56 TAXUS V 56 tipifarnib 56 Syllego system 56 GFT# 56 Phase III Clinical Trial 56 Phase IIB 56 entinostat 56 endometrial adenocarcinoma 56 SORT OUT III 56 virologic response 56 atherothrombotic disease 56 p# biomarker 56 BCR ABL1 55 oral ridaforolimus 55 sorafenib tablets 55 pazopanib 55 Bipolar Disorders 55 heavily pretreated 55 Poster Discussion 55 multicenter multinational 55 CHARISMA trial 55 IIa clinical 55 ELSO 55 EXPAREL ™ 55 dose melphalan 55 NOX E# 55 ATIR 55 HIF PHI 55 Tyrima 55 MT#/MEDI-# 55 CombAT 55 PRTX 55 #nd EORTC NCI 55 Anticancer Drug 55 SYNTAX trial 55 Symadex 55 alvespimycin 55 Phase IIA 55 Cancer Incidence Mortality 55 Am J Pathol 55 ENDEAVOR II 55 interferon gamma 1b 55 Marrow Transplant 55 annexin 55 EDRN 55 European CanCer Organisation ECCO 55 ACCORD Lipid 55 Lodotra TM 55 Thrombolysis 55 retrospective cohort study 55 virological response 55 erlotinib Tarceva ® 55 phase III ACCLAIM 55 Cancer Epidemiol Biomarkers Prev 55 chemoradiation 55 CEQ# 55 null responder HCV 55 refractory prostate cancer 55 Cancers Symposium 55 Kaplan Meier analysis 55 Torisel 55 IMiDs ® compound 55 FDG PET 55 Zenvia Phase III 55 COMFORT II 55 AVAiL 55 metastatic colorectal 55 CYT# 55 APTIVUS 55 EUROCARE 55 plus prednisone 55 Gynecol Oncol 55 Randomized Phase III 55 relapsed refractory 55 tubulin inhibitor 55 ASSERT trial 55 HDL Selective Delipidation 55 retrospective cohort 55 Inflammatory Bowel Diseases 55 landmark ATHENA trial 55 metastatic pancreatic 55 HER2 expression 55 Dose Escalation 55 CIN2 + 55 Prednisone Against Refractory 55 Br J Cancer 55 J Clin Endocrinol Metab 55 Randomized Double blind 55 Akt inhibitor 55 AIDS Clinical Trials 55 K ras mutations 55 ADVEXIN therapy 55 PegIFN RBV 55 Oncogene 55 Glufosfamide 55 Randomized Phase 55 recurrent NSCLC 55 nomograms 55 VESTASYNC 55 CHARM Added 55 #F FDG PET CT 55 lintuzumab 55 AVOREN 55 NATRECOR ® 55 Thoracic Oncology 55 metastatic castration resistant 55 Phase IIa clinical 55 Solid Tumours 55 pediatric acute lymphoblastic 55 Kinase Inhibitor 55 Meta analyzes 55 eribulin mesylate 55 stage IIIb IV 55 Nat Med 55 ALLHAT 55 PROLARIS 55 Phase IIb trial 55 Bortezomib 55 demonstrated antitumor activity 55 pharmacoeconomic analysis 55 antitumor effects 55 PRIMO CABG 55 observational cohort study 55 Brentuximab Vedotin SGN 55 vaso occlusive crisis 55 TORISEL 55 ARVO 55 underwent resection 55 ataluren 55 ILLUMINATE 55 Phase III multicenter 55 EpCAM 55 trastuzumab DM1 T DM1 55 secondary efficacy endpoint 55 CLARITY TIMI 55 CALERIE 55 ritonavir boosted 55 #p# [003] 55 metastatic renal cell 55 novel histone deacetylase 55 LEXIVA r 55 Initiated Phase 55 Ann Oncol 55 TEMODAL 55 Gastrointestinal Oncology 55 Respiratory Society 55 Prostate Cancer Prevention 55 liver resection 55 Cytochrome P# 55 delafloxacin 55 Acute Stroke 55 INGN 55 Castration Resistant Prostate Cancer 55 PEG SN# 55 Combination REOLYSIN R 55 iPrEx 55 PROactive study 55 follicular lymphoma FL 55 Cutaneous T 55 Hepatocellular Carcinoma HCC 55 Certican 55 NADiA ProsVue 55 T#I [002] 55 Dr. McHutchison 55 MDACC 55 huC# DM4 55 JAK inhibitor 55 randomized Phase 2b 55 Randomized controlled 55 IRESSA 55 GISSI 55 Dr. Pingpank 55 relapsed ovarian cancer 55 Alpharadin 55 oral prodrug 55 Gastrointestinal Cancer 55 angiogenesis inhibitor 55 JAK2 V#F 55 AIR CF3 55 SSc patients 55 Tumor Microenvironment 55 PRECISE 55 Waldenstrom Macroglobulinemia 55 clinico pathological 55 Archexin 55 clinical endpoints 55 FOLFIRI 55 treatment naive genotype 55 histopathological 55 randomized clinical 55 urothelial carcinoma 55 Phase 2a clinical 55 retrospective observational study 55 ABVD 55 favorable pharmacokinetic profile 55 pharmacodynamics PD 55 clinicopathologic 55 mCRC 55 darunavir r 55 GSK# [001] 55 ALN TTR 55 gadobutrol 55 BCG refractory 55 hepatocellular carcinoma HCC 55 transthyretin TTR mediated amyloidosis 55 epithelial tumors 55 CanAg 55 TroVax ® 55 CTEPH 55 CUSTOM III 55 OHR/AVR# 55 CC genotype 55 J Immunol 55 ARBITER 6 55 operable breast cancer 55 CATIE 55 resected pancreatic cancer 55 Teriflunomide 55 oral diclofenac 55 oblimersen 55 Eur Respir J 55 confirmatory clinical 55 Myocardial Infarction Study 55 J Clin Invest 55 Proc Am Soc 55 Elacytarabine 55 immatics 55 tolvaptan 55 essential thrombocythemia ET 55 Azacitidine 55 novel VDA molecule 55 Oncotype 55 cisplatin vinorelbine 55 Systemic Sclerosis 55 concurrent chemoradiation 55 colorectal carcinoma 55 Ovarian Cancer Screening 55 Cardiostim 55 ONTARGET R 55 motesanib diphosphate 55 CYPHER Stent 55 Primary endpoints 55 European CanCer Organisation 55 antiangiogenic agent 55 longitudinal observational study 55 EINSTEIN DVT 55 Elagolix 55 melphalan prednisone 55 recurrent glioma 55 IMPROVE IT 55 BZL# 55 PRIMO CABG2 55 Onrigin 55 ASBMR 55 underwent surgical resection 55 ACCOMPLISH 55 RezularTM 55 NPC 1C 55 Phase IIb clinical trials 55 SVR# 55 varespladib 55 oral rivaroxaban 55 XELOX 55 KRN# 55 AEGR 55 Clin Chem 55 secondary efficacy endpoints 55 Kidney Int 55 PCA3 test 55 relapsing multiple sclerosis 55 pharmacodynamic properties 55 CYT# potent vascular disrupting 55 MammaPrint R 55 IMGN# 55 Multicentre 55 Oncotype DX Recurrence Score 55 eprotirome 55 thyroglobulin 55 PANVAC VF 54 AAG geldanamycin analog 54 Dr. Guido Marcucci 54 Neuvenge 54 AIM HIGH 54 Newly Diagnosed Multiple Myeloma 54 cediranib 54 Nat Genet 54 INC# 54 ACTIVE W 54 obatoclax 54 AVN# Phase 54 San Antonio Breast Cancer 54 StemEx R 54 Zemplar Capsules